Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Treatment of acromegaly with somatostatin analogs (SA) is well-established and are primarily
used after insufficient surgical intervention, but also as primary medical treatment in
selected patients. Evaluation of treatment control is based on monitoring blood levels of
growth hormone (GH) and insulin-like growth factor-I (IGF-I). However, evaluation of disease
control during SA treatment is not always straightforward. It is usually based on
normalization of IGF-I and achievement of a certain GH level. In approximately 40% of
patients discordant values of GH and IGF-I levels are seen after treatment with SA, with
normalized IGF-I levels, despite elevated GH levels. The mechanism behind this observation is
unknown, but it indicates that SA may affect this difference.
The primary objective of this study is to investigate if disease control during SA treatment
is best achieved by monitoring either GH or IGF-I.
Phase:
Phase 4
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Aarhus University Hospital Copenhagen University Hospital, Denmark Herlev Hospital Odense University Hospital